ABL Diagnostics Signs Contract Potentially Worth €2.7M Through 2031
ABL Diagnostics announced on Friday the signing of a multi-year agreement with a European pharmaceutical company specializing in neurodegenerative diseases. Operated by its sister company CDL Pharma, the contract extends until 2031 and could reach a total value of €2.7M.
Integrated Services for International Clinical Trials
The contract involves operational services carried out by CDL Pharma and distributed by ABL Diagnostics. It covers the operational management of international clinical trials, logistics and transportation of biological samples, design and management of collection kits, cryogenic storage, and biomarker analysis. The partnership is part of a clinical program involving 30 centers across 11 countries (North America, Europe, and Asia). ABL Diagnostics acts as the distributor of these services to the end client. Mohamed Errafyqy, Director of Sales and Operations at ABL Diagnostics, stated: "This contract demonstrates our ability to support complex clinical programs and to offer integrated service solutions."
Amounts and Revenue Recognition Schedule
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The agreement includes an initial payment of over €100,000 upon signing. The total contractual value could reach approximately €2.7M by 2031. Revenues will be recognized progressively based on the actual performance of services and will depend on the real progress of the clinical program. This contract helps to improve the visibility of future revenues over several financial years and illustrates the gradual development of ABL Diagnostics' value-added services in international clinical research.
Promising Market of Neurodegenerative Diseases
The market for neurodegenerative diseases benefits from favorable structural trends, driven particularly by the aging population and the emergence of new therapeutic approaches. According to sector reports published by Mordor Intelligence and Research and Markets, this market could reach approximately $88 billion by 2030-2031. These estimates are based on growth assumptions that remain uncertain and do not constitute a prediction of the actual market developments or the potential share of ABL Diagnostics. The demand for services related to clinical trials, including logistics of biological samples and biomarker analysis, is expected to grow as clinical programs become more complex, with no assurance as to its extent or timing.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 12,3 millions d'euros
Management commentary: On June 1, 2026, ABL Diagnostics published a roadmap targeting annual revenue of €12.265 million in 2026, compared to €6.950 million in 2025, i.e. a targeted annual growth of 76.5%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
